Last reviewed · How we verify
Bevacizumab as MYL-1402O
Bevacizumab as MYL-1402O is a Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent Biologic drug developed by Mylan Pharmaceuticals Inc. It is currently in Phase 3 development for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.
MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | Bevacizumab as MYL-1402O |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Drug class | Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling protein that promotes the formation of new blood vessels. By blocking VEGF, the drug starves tumors of their blood supply, slowing or halting tumor growth. MYL-1402O is Mylan's biosimilar version designed to have equivalent efficacy and safety to the reference bevacizumab product.
Approved indications
- Metastatic colorectal cancer
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
- Glioblastoma
- Metastatic renal cell carcinoma
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
- Diarrhea
Key clinical trials
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (PHASE3)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab as MYL-1402O CI brief — competitive landscape report
- Bevacizumab as MYL-1402O updates RSS · CI watch RSS
- Mylan Pharmaceuticals Inc portfolio CI
Frequently asked questions about Bevacizumab as MYL-1402O
What is Bevacizumab as MYL-1402O?
How does Bevacizumab as MYL-1402O work?
What is Bevacizumab as MYL-1402O used for?
Who makes Bevacizumab as MYL-1402O?
What drug class is Bevacizumab as MYL-1402O in?
What development phase is Bevacizumab as MYL-1402O in?
What are the side effects of Bevacizumab as MYL-1402O?
What does Bevacizumab as MYL-1402O target?
Related
- Drug class: All Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent drugs
- Target: All drugs targeting VEGF (Vascular Endothelial Growth Factor)
- Manufacturer: Mylan Pharmaceuticals Inc — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Metastatic non-small cell lung cancer
- Indication: Drugs for Metastatic breast cancer
- Compare: Bevacizumab as MYL-1402O vs similar drugs
- Pricing: Bevacizumab as MYL-1402O cost, discount & access